or Try an Advanced Search...

    Technical Analysis for VSTM - Verastem, Inc.

    Grade Last Price % Change Price Change
    F 9.22 -1.02% -0.10
    VSTM closed down 1.02 percent on Thursday, April 25, 2024, on 51 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: May 7
    *** please verify all earnings dates ***
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical VSTM trend table...
    Date Alert Name Type % Chg
    Lower Bollinger Band Walk Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Down 5 Days in a Row Weakness 0.00%
    Gapped Down Weakness 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Fell Below 200 DMA Bearish -1.02%
    Lower Bollinger Band Walk Weakness -1.02%
    Older End-of-Day Signals for VSTM ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout about 13 hours ago
    Rose Above Lower Bollinger Band about 16 hours ago
    Fell Below Previous Day's Low about 16 hours ago
    Down 2 % about 16 hours ago
    Down 1% about 16 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    VSTM Chart by TradingView
    Basic chart:

    Profile

    Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing proprietary small molecule drugs targeting cancer stem cells (CSCs) with companion diagnostics. Its programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. The company's lead FAK inhibitor, VS-6063, is in Phase I/Ib testing in ovarian cancer, as well as developing for the treatment of mesothelioma and breast cancer. It is also developing FAK inhibitor VS-4718 and PI3K/mTOR inhibitor VS-5584 in patients with advanced cancers. The company's product candidates target CSCs that have been implicated in aggressive cancers, metastasis, and chemotherapeutic resistance. Verastem, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Cancer Oncology Stem Cell Breast Cancer Ovarian Cancer Treatment Of Breast Cancer Signal Transduction mTOR Cancer Research Companion Diagnostic Metastasis Advanced Cancer Mesothelioma Advanced Cancers Cancer Stem Cell Cancer Stem Cells Mtor Inhibitors

    Is VSTM a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 18 Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
    Apr 4 Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Mar 18 Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer
    Mar 14 Recap: Verastem Q4 Earnings
    Mar 14 Verastem GAAP EPS of -$1.02 misses by $0.21
    Mar 14 Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
    Mar 11 Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs
    Mar 6 Verastem gets FDA orphan drug status for low-grade ovarian cancer therapy
    Mar 5 Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
    Mar 5 Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024
    See more VSTM news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 15.18
    52 Week Low 4.56
    Average Volume 139,191
    200-Day Moving Average 9.60
    50-Day Moving Average 11.54
    20-Day Moving Average 10.93
    10-Day Moving Average 10.21
    Average True Range 0.61
    RSI (14) 28.57
    ADX 18.79
    +DI 11.94
    -DI 29.51
    Chandelier Exit (Long, 3 ATRs) 10.43
    Chandelier Exit (Short, 3 ATRs) 10.86
    Upper Bollinger Bands 12.73
    Lower Bollinger Band 9.13
    Percent B (%b) 0.02
    BandWidth 33.01
    MACD Line -0.59
    MACD Signal Line -0.37
    MACD Histogram -0.217
    Fundamentals Value
    Market Cap 232.85 Million
    Num Shares 25.3 Million
    EPS -3.89
    Price-to-Earnings (P/E) Ratio -2.37
    Price-to-Sales 51.84
    Price-to-Book 4.01
    PEG Ratio -1.89
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 9.74
    Resistance 3 (R3) 9.74 9.56 9.65
    Resistance 2 (R2) 9.56 9.42 9.56 9.62
    Resistance 1 (R1) 9.39 9.34 9.47 9.39 9.59
    Pivot Point 9.21 9.21 9.25 9.21 9.21
    Support 1 (S1) 9.04 9.07 9.12 9.04 8.84
    Support 2 (S2) 8.86 8.99 8.86 8.81
    Support 3 (S3) 8.69 8.86 8.78
    Support 4 (S4) 8.69